Arrowhead Research Corp. (NASDAQ:ARWR) shares rose 2.1% during trading on Tuesday . The stock traded as high as $6.30 and last traded at $6.25, with a volume of 396,671 shares. The stock had previously closed at $6.12.

ARWR has been the subject of several research analyst reports. Jefferies Group reiterated a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Cantor Fitzgerald started coverage on Arrowhead Research Corp. in a report on Wednesday. They set a “buy” rating and a $15.00 price target for the company. Piper Jaffray Cos. dropped their price target on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Vetr raised Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 price target for the company in a report on Wednesday, April 20th. Finally, Chardan Capital started coverage on Arrowhead Research Corp. in a report on Thursday, May 19th. They set a “buy” rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Research Corp. has a consensus rating of “Buy” and an average target price of $10.44.

The company’s market capitalization is $385.16 million. The firm’s 50-day moving average is $5.79 and its 200 day moving average is $5.24.

Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. During the same period last year, the company earned ($0.27) earnings per share. The company earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. The business’s revenue for the quarter was down 68.0% compared to the same quarter last year. Equities analysts anticipate that Arrowhead Research Corp. will post ($1.30) earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.